Abstract: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.

Abstract: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins or fragments thereof.

Abstract: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins or fragments thereof.

Abstract: Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (?2GPI) monoclonal antibodies (mAbs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-?2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.

Abstract: A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.

Abstract: Methods and compositions employing beta2-glycoprotein-1 (?2GPI) or derivatives of ?2GPI effective in inducing mucosal tolerance to atheroma related antigens, thus inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae, are provided. Also provided are articles of manufacture comprising mucosal tolerance inducing amounts of beta2-glycoprotein-1 46 (?2GPI) or derivatives thereof.

Abstract: A method for prevention and/or treatment of atherosclerosis in a subject, in need thereof is disclosed. The method is effected by orally administering to the subject an immunological oral tolerance-inducing composition which comprises an immunological oral tolerance-inducing amount of an active ingredient selected from the group consisting of beta2-glycoprotein-1 (?2GP-1) or a derivative of ?2GP-1.

Abstract: Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (?2GPI) monoclonal antibodies (mAbs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-?2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.

Abstract: Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (&bgr;2GPI) monoclonal antibodies (mabs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-&bgr;2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.

Abstract: An immunological oral tolerance-inducing composition for prevention and/or treatment of atherosclerosis, comprising an active component selected from the group consisting of modified low density lipoprotein, oxidized low density lipoprotein (Ox LDL), heat shock protein 60/65 (HSP 60/65), beta2-glycoprotein-1(?2GP-1), functional derivatives thereof and mixtures thereof, in combination with a pharmaceutically acceptable carrier for oral administration.

Abstract: An immunological oral tolerance-inducing composition for prevention and/or treatment of atherosclerosis, comprising an active component selected from the group consisting of modified low density lipoprotein, oxidized low density lipoprotein (Ox LDL), heat shock protein 60/65 (HSP 60/65), beta2-glycoprotein-1(&bgr;2GP-1), functional derivatives thereof and mixtures thereof, in combination with a pharmaceutically acceptable carrier for oral administration.

Abstract: A method for the treatment of fibrous-deposition conditions (FDC) comprising administrating intravenous immunoglobulin (IVIG) as an active ingredient.

Abstract: This invention provides therapeutic methods for inhibiting tumor metastasis and for treating primary tumors. The methods of this invention do not cause serious side effects and will be effective for a broad spectrum of cancerous diseases. In particular, the invention discloses a novel method comprising administering to a mammal a preparation of intravenous immunoglobulin (IVIG). The IVIG preparation to be administered according to this invention may contain intact immunoglobulin molecules or fragments of immunoglobulins. The preparation is administered parenterally, preferably via intravenous, intracavitary or subcutaneous routes, either as a sole agent or in combination with other agents or methods which are commonly used for cancer treatment.

Abstract: This invention provides therapeutic methods for inhibiting tumor metastasis and for treating primary tumors. The methods of this invention do not cause serious side effects and will be effective for a broad spectrum of cancerous diseases. In particular, the invention discloses a novel method comprising administering to a mammal a preparation of intravenous immunoglobulin (IVIG). The IVIG preparation to be administered according to this invention may contain intact immunoglobulin molecules or fragments of immunoglobulins. The preparation is administered parenterally, preferably via intravenous, intracavitary or subcutaneous routes, either as a sole agent or in combination with other agents or methods which are commonly used for cancer treatment.